Drug Trial Radar · NCT07445763
TARSILA Real-World Evidence Study
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
5,000
Planned (sponsor's estimate)
Start
Apr 27, 2026
Primary completion
Sep 30, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Inova MedicalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Universidade Federal do Paraná
- First posted
- Mar 3, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 360 days
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall objective of Tarsila Study is to estimate the real-world vaccine effectiveness of maternal RSVpreF immunization during pregnancy in Brazil against medically attended (inpatient and outpatient) respiratory syncytial virus-associated acute respiratory illness in infants. To achieve this, two multicenter, prospective, test-negative case-control studies will be conducted among infants with ARI: the TARSILA Inpatient Study, evaluating hospitalized infants and the TARSILA Outpatient Study, evaluating infants managed in outpatient settings.
Conditions
- Respiratory Syncytial Virus (RSV)
- Maternal Immunization
- Acute Respiratory Illness (ARI)
- Lower Respiratory Tract Disease
- Infant Outcomes
Interventions
respiratory syncytial virus bivalent prefusion F vaccineBiological
For both studies, the primary exposure is maternal receipt of respiratory syncytial virus bivalent prefusion F vaccination during pregnancy in accordance with the Brazilian National Immunization Program recommendation (24⁺⁰/₇ to 36⁺⁶/₇ weeks' gestation) with the receipt of the vaccine 14 days or more before delivery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Lower respiratory Tract Disease (LRTD) Hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)Time frame: Hospitalization occurring ≤180 days after birth
- Acute respiratory illness (ARI) among infants aged up to 180 days (Tarsila Outpatient Study)Time frame: Occurring ≤180 days after birth.
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Unidade de Pronto Atendimento Veneza
Cascavel, Paraná, Brazil · Recruiting
Complexo do Hospital de Clínicas da Universidade Federal do Paraná
Curitiba, Paraná, Brazil · Recruiting
Hospital Infantil Pequeno Príncipe
Curitiba, Paraná, Brazil · Recruiting
Unidade de Pronto Atendimento 24 Horas Dr. Edgar Netzel
Marechal Cândido Rondon, Paraná, Brazil · Recruiting
Unidade de Saúde Central de Palotina
Palotina, Paraná, Brazil · Recruiting
Unidade de Pronto Atendimento II de Toledo
Toledo, Paraná, Brazil · Recruiting
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Hospital Nossa Senhora da Conceição
Porto Alegre, Rio Grande do Sul, Brazil · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.